NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IONS Stock Alerts $42.45 +0.61 (+1.46%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$41.59▼$42.7250-Day Range$40.68▼$49.0752-Week Range$34.32▼$54.44Volume731,441 shsAverage Volume1.14 million shsMarket Capitalization$6.19 billionP/E RatioN/ADividend YieldN/APrice Target$56.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ionis Pharmaceuticals alerts: Email Address Ionis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside32.6% Upside$56.08 Price TargetShort InterestBearish7.11% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.48Based on 15 Articles This WeekInsider TradingSelling Shares$2.56 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.00) to ($3.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.19 out of 5 starsMedical Sector136th out of 909 stocksPharmaceutical Preparations Industry47th out of 423 stocks 4.3 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.11% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 1.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 1.9 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Ionis Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,556,127.00 in company stock.Percentage Held by InsidersOnly 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($4.00) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -16.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -16.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 15.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Ionis Pharmaceuticals Stock (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesApril 18, 2024 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi Sells 4,006 SharesApril 23, 2024 | prnewswire.comIonis to hold first quarter 2024 financial results webcastApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 19, 2024 | americanbankingnews.comJoseph Baroldi Sells 4,006 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockApril 18, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Lowered by AnalystApril 18, 2024 | americanbankingnews.comIonis Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.09 Per Share (NASDAQ:IONS)April 15, 2024 | nasdaq.comIONS Quantitative Stock AnalysisApril 12, 2024 | msn.comWolfe upgrades Ionis to outperform, cites upcoming catalystsApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 11, 2024 | investing.comIonis Pharmaceuticals stock upgraded to OutperformApril 11, 2024 | investing.comIonis Pharmaceuticals stock upgraded to OutperformApril 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)April 8, 2024 | markets.businessinsider.comIonis Pharmaceuticals Faces Sell Rating Amid Weak Clinical Results and Rising CompetitionApril 8, 2024 | markets.businessinsider.comBuy Rating on Ionis Pharmaceuticals: Promising Clinical Data and Strategic Market Positioning for OlezarsenApril 8, 2024 | msn.comIonis experimental drug meets key goal in familial chylomicronemia studyApril 8, 2024 | finanznachrichten.deIonis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeApril 7, 2024 | prnewswire.comIonis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeApril 1, 2024 | prnewswire.comIonis to present at upcoming investor conferencesMarch 28, 2024 | prnewswire.comIonis to hold olezarsen Phase 3 data webcastMarch 25, 2024 | prnewswire.comPositive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingMarch 22, 2024 | finance.yahoo.comIonis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?March 17, 2024 | ca.finance.yahoo.comIONS Oct 2024 50.000 putMarch 16, 2024 | msn.comNASH drug market expected to surpass $48B by 2035March 16, 2024 | finance.yahoo.comIONS Apr 2024 75.000 callMarch 14, 2024 | finance.yahoo.comQ4 2023 Agenus Inc Earnings Call and Corporate UpdateMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemed (CHE), Ionis Pharmaceuticals (IONS) and Arcellx Inc (ACLX)March 14, 2024 | finance.yahoo.comMadrigal wins FDA approval of first drug for MASHSee More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/24/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees927Year FoundedN/APrice Target and Rating Average Stock Price Target$56.08 High Stock Price Target$75.00 Low Stock Price Target$28.00 Potential Upside/Downside+31.9%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-366,290,000.00 Net Margins-46.32% Pretax Margin-42.40% Return on Equity-90.29% Return on Assets-12.39% Debt Debt-to-Equity Ratio3.18 Current Ratio5.90 Quick Ratio5.83 Sales & Book Value Annual Sales$788 million Price / Sales7.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.70 per share Price / Book15.75Miscellaneous Outstanding Shares145,750,000Free Float141,888,000Market Cap$6.20 billion OptionableOptionable Beta0.39 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 63)Founder, CEO & Director Comp: $1.71MMs. Elizabeth L. Hougen M.A. (Age 62)M.B.A., M.S., Executive VP of Finance & CFO Comp: $1.02MMs. B. Lynne Parshall Esq. (Age 70)J.D., Senior Strategic Advisor & Director Comp: $334.64kDr. Richard S. Geary Ph.D. (Age 66)Executive VP & Chief Development Officer Comp: $946.26kMr. Joseph T. Baroldi M.A. (Age 45)M.B.A., M.S., Executive VP & Chief Business Officer Comp: $815.87kMr. Darren GonzalesChief Accounting Officer & Senior VPDr. C. Frank Bennett BSc (Age 67)Ph.D., Executive VP & Chief Scientific Officer Comp: $651.64kMr. D. Wade Walke Ph.D.Senior Vice President of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 50)Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary Comp: $815.69kMs. Hayley SofferVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDGeronNASDAQ:GERNDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 86,862 shares on 4/24/2024Ownership: 0.186%Simplicity Wealth LLCBought 16,229 shares on 4/24/2024Ownership: 0.011%Fifth Third BancorpBought 351 shares on 4/23/2024Ownership: 0.007%Raymond James & AssociatesSold 71,122 shares on 4/22/2024Ownership: 0.077%Handelsinvest InvesteringsforvaltningSold 2,746 shares on 4/19/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions IONS Stock Analysis - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price target for 2024? 13 Wall Street research analysts have issued 12 month price objectives for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $28.00 to $75.00. On average, they predict the company's share price to reach $56.08 in the next year. This suggests a possible upside of 32.6% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2024? Ionis Pharmaceuticals' stock was trading at $50.59 at the start of the year. Since then, IONS shares have decreased by 16.4% and is now trading at $42.28. View the best growth stocks for 2024 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our IONS earnings forecast. How can I listen to Ionis Pharmaceuticals' earnings call? Ionis Pharmaceuticals will be holding an earnings conference call on Tuesday, May 7th at 11:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.72. The company earned $325 million during the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 90.29% and a negative net margin of 46.32%. Ionis Pharmaceuticals's quarterly revenue was up 113.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.37) EPS. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), Horizon Kinetics Medical ETF (MEDX), Invesco Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), Tema Cardiovascular and Metabolics ETF (HRTS), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.19%), Sumitomo Mitsui Trust Holdings Inc. (0.15%), Raymond James & Associates (0.08%), Simplicity Wealth LLC (0.01%), Fifth Third Bancorp (0.01%) and International Assets Investment Management LLC (0.01%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Baroldi, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IONS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
